SK pharmteco today announced the launch of SKyvec™, its proprietary, multimodal viral vector platform. Designed to support gene therapy programs at every stage, from early research through clinical ...
Learn how viral vector release testing for AAV and lentiviral vectors utilizes orthogonal assays for titer, capsid content, ...
Monkey-virus-derived SRV2 envelope protein improves anti-tumor efficacy over conventional RD114 carriers in Nature ...
LumaCyte today announced that its analytical approach has been included in the newly published International Organization for Standardization (ISO) global standard for gene delivery systems, ISO 16921 ...
Despite four decades of effort, neither a cure nor a preventive vaccine exists for HIV-1. HIV-1 vaccine development faces persistent barriers, including the rapid mutation rate of the virus, its ...
A research team led by Park Ji-hoon at the Korea Research Institute of Chemical Technology has developed a new gene delivery ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
Chimeric antigen receptor (CAR)-T cell therapy medicinal products constitute the paradigm shift in cancer immunotherapy, employing genetic engineering to endow T cells with the capacity for precise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results